- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc stock price live, this page displays NASDAQ APLS stock exchange data. View the APLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Apellis Pharmaceuticals Inc real time stock price chart below.
What Is the Apellis Pharmaceuticals Inc Stock Price Today?
The Apellis Pharmaceuticals Inc stock price today is 21.31.
What Is the Stock Symbol for Apellis Pharmaceuticals Inc?
The stock symbol for Apellis Pharmaceuticals Inc is "APLS."
What Stock Exchange Does Apellis Pharmaceuticals Inc Trade On?
Apellis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Apellis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Apellis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the APLS quote. (ISIN: US03753U1060)
What Is the Apellis Pharmaceuticals Inc Stock Price Today?
The Apellis Pharmaceuticals Inc stock price today is 21.31.
What Is the Stock Symbol for Apellis Pharmaceuticals Inc?
The stock symbol for Apellis Pharmaceuticals Inc is "APLS."
What Stock Exchange Does Apellis Pharmaceuticals Inc Trade On?
Apellis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Apellis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Apellis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the APLS quote. (ISIN: US03753U1060)
Currency in USD
21.31
-0.82(-3.71%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.94
22.40
52 wk Range
16.10
30.48
APLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.9422.40
52 wk Range
16.1030.48
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
APLS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
33.58
Upside
+57.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
- Apellis Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Apellis Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Apellis Pharmaceuticals Inc Company Profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
Apellis Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Q4 2025 revenue reached $200M, exceeding forecast of $198.82M; full-year revenue hit $1B including $275M one-time payment.
- Syfovre generated $155M and Empaveli $35M in Q4; strong product demand continues despite 6.36% pre-market stock decline to $21.04.
- Operating expenses rose to $251M from $239M year-over-year, driven by new pivotal trials and milestone payments.
- 2026 guidance projects modestly higher expenses; planned Syfovre prefilled syringe launch and AI-enabled OCT technology development underway.
- Company managing $94M convertible debt maturing September 2026; maintains strong liquidity with 3.54 current ratio.
Last Updated: 2026-02-24, 09:48 a/m
Read Full TranscriptCompare APLS to Peers and Sector
Metrics to compare | APLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 120.8x | 14.0x | −0.6x | |
PEG Ratio | 1.10 | 0.29 | 0.00 | |
Price/Book | 7.3x | 6.9x | 2.6x | |
Price / LTM Sales | 2.7x | 7.7x | 3.3x | |
Upside (Analyst Target) | 31.2% | 149.6% | 45.1% | |
Fair Value Upside | Unlock | 12.8% | 5.5% | Unlock |
Analyst Ratings
14 Buy
7 Hold
1 Sell
Ratings:
22 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 33.58
(+57.57% Upside)
Earnings
Latest Release
Feb 24, 2026
EPS / Forecast
0.47 / -0.38
Revenue / Forecast
199.91M / 198.82M
People Also Watch
FAQ
What Is the Apellis Pharma (APLS) Stock Price Today?
The Apellis Pharma stock price today is 21.31 USD.
What Stock Exchange Does Apellis Pharma Trade On?
Apellis Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Apellis Pharma?
The stock symbol for Apellis Pharma is "APLS."
What Is the Apellis Pharma Market Cap?
As of today, Apellis Pharma market cap is 2.73B USD.
What Is Apellis Pharma's Earnings Per Share (TTM)?
The Apellis Pharma EPS (TTM) is 0.18.
When Is the Next Apellis Pharma Earnings Date?
Apellis Pharma will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is APLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Apellis Pharma Stock Split?
Apellis Pharma has split 0 times.
How Many Employees Does Apellis Pharma Have?
Apellis Pharma has 708 employees.
What is the current trading status of Apellis Pharma (APLS)?
As of Feb 25, 2026, Apellis Pharma (APLS) is trading at a price of 21.31 USD, with a previous close of 22.13 USD. The stock has fluctuated within a day range of 20.94 USD to 22.40 USD, while its 52-week range spans from 16.10 USD to 30.48 USD.
What Is Apellis Pharma (APLS) Price Target According to Analysts?
The average 12-month price target for Apellis Pharma is 33.58 USD, with a high estimate of 55 USD and a low estimate of 18 USD. 14 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +57.57% Upside potential.
What Is the APLS Premarket Price?
APLS's last pre-market stock price is 21.90 USD. The pre-market share volume is 610.00, and the stock has decreased by -0.23, or -1.04%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.